FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
110129.420C2APPLICATION NO.  
09/865,195

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT  
William L. HunterFILING DATE  
May 24, 2001GROUP ART UNIT  
Not Yet Assigned

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BS	AA	6,159,143	12/12/00	Lennox	600	4	
	AB	6,096,923	08/01/00	McWilliams and Sapino	564	33	
	AC	6,080,874	06/27/00	Hengeveld et al.	549	58	
	AD	5,843,903	12/01/98	Schally et al.	514	16	
	AE	5,665,768	09/09/97	Kawai and Stevens	514	471	
	AF	5,602,140	02/11/97	Isobe et al.	514	262	
	AG	5,594,158	01/14/97	Desmond M. S. Wheeler	552	201	
	AH	5,552,156	09/03/96	Thomas G. Burke	424	450	
	AI	5,527,905	06/18/96	Sugimura et al.	540	201	
BS	AJ	5,472,956	12/05/95	Borch and Schmidt	514	95	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
BS	AK	WO 93/10076	05/27/93	WIPO		
	AL	WO 96/14880	05/23/96	WIPO		
	AM	WO 97/19706	06/05/97	WIPO		
BS	AN	WO 99/65532	12/13/99	WIPO		
	AO					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	
	AQ	
	AR	

EXAMINER

Brian Szma

DATE CONSIDERED

12-5-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV.7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
110129.420C2APPLICATION NO.  
09/865,195

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT  
William L. HunterFILING DATE  
May 24, 2001GROUP ART UNIT  
Not Yet Assigned

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BR	BA	5,446,139	08/29/95	Seela et al.	536	26.7	
	BB	5,440,056	08/08/95	Klein et al.	549	510	
	BC	5,409,915	04/25/95	Farrell et al.	514	187	
	BD	5,382,582	01/17/95	Carcy L. Chan	514	249	
	BE	5,380,897	01/10/95	Hoeschele et al.	556	137	
	BF	5,292,731	03/08/94	Bernard Loev	514	186	
	BG	5,215,738	06/01/93	Lee et al.	424	10	
	BH	5,190,929	03/02/93	Borch and Canute	514	80	
	BI	5,166,149	11/24/92	Bernard Loev	514	186	
	BJ	5,066,658	11/19/91	Demers and Sulsky	514	269	
	BK	5,047,528	09/10/91	Kutney et al.	540	478	
	BL	5,034,320	07/23/91	Tsuyoshi Endo	435	119	
	BM	5,030,620	07/09/91	Hannart et al.	514	18	
	BN	4,923,876	05/08/90	Francis and Kasubick	514	283	
BR	BO	4,908,356	03/13/90	Borch and Valente	514	90	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BP					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BQ	
	BR	

EXAMINER

Brian Sema

DATE CONSIDERED

12-5-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
110129.420C2APPLICATION NO.  
09/865,195

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT  
William L. HunterFILING DATE  
May 24, 2001GROUP ART UNIT  
Not Yet Assigned

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BS	CA	4,841,085	06/20/89	Farquhar and Wang	538	180	
	CB	4,841,045	06/20/89	Martin Kuehne	540	478	
	CC	4,828,831	05/09/89	Hannart et al.	424	85.91	
	CD	4,767,855	08/30/88	Tarroux et al.	540	478	
	CE	4,763,642	8/16/88	Horowitz	128	1.2	
	CF	4,639,456	01/27/87	Trouet et al.	514	283	
	CG	4,588,831	05/13/86	Sagredos et al.	556	137	
	CH	4,472,379	09/18/84	Tetsuo Suami	424	177	
	CI	4,375,432	03/01/83	Robert A. Conrad	260	244.4	
	CJ	4,374,987	02/22/83	Singh and Schaefer	544	260	
	CK	4,367,239	01/04/83	Bregnedal and Buus	424	322	
	CL	4,299,778	11/10/81	Kurt H. Pilgram	260	500.5 H	
	CM	4,296,105	10/20/81	Baurain and Trouet	424	180	
	CN	4,259,242	03/31/81	Stanislaw Rolski	260	244.4	
BS	CO	4,258,052	03/24/81	Yu and Scott	424	266	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CP					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CQ	
	CR	


EXAMINER

Brian Szura

DATE CONSIDERED

12-5-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.420C2	APPLICATION NO. 09/865,195
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>			APPLICANT William L. Hunter	
			FILING DATE May 24, 2001	GROUP ART UNIT Not Yet Assigned

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BB	DA	4,250,189	02/10/81	Hydes and Watkins	424	287	
	DB	4,215,062	07/29/80	Lester A. Mitscher	260	365	
	DC	4,210,584	07/01/80	Paschal and Thompson	260	244.4	
	DD	4,150,146	04/17/79	Gerhard Eisenbrand	424	322	
	DE	4,145,414	03/20/79	Kelly and Wechter	424	180	
	DF	4,144,237	03/13/79	James P. Kutney	260	244.4	
	DG	4,086,417	04/25/78	Ishida et al.	536	29	
	DH	4,057,548	11/08/77	Jacek Wiecko	260	250 BC	
	DI	4,012,390	03/15/77	George J. Cullinan	260	287 B	
	DJ	3,991,045	11/09/76	Ishida et al.	536	23	
	DK	3,894,000	07/08/75	Wechter and Warner	260	211.5 R	
	DL	3,808,297	04/30/74	Takamizawa and Iwata	260	936	
	DM	3,387,001	06/04/68	William W. Hargrove	260	287	
BB	DN	Re. 30,561	03/31/81	Miller and Gutowski	260	244.4	
	DO						
	DP						

## FOREIGN PATENT DOCUMENTS


		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	DQ					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	DR	
	DS	

EXAMINER <i>Brian Szmal</i>	DATE CONSIDERED <i>12-5-02</i>
--------------------------------	-----------------------------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
110129.420C2APPLICATION NO.  
09/865,195

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT  
William L. Hunter et al.FILING DATE  
May 24, 2001GROUP ART UNIT  
3738RECEIVED  
APR 10 2001  
TECHNOLOGY CENTER P5700

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BS	AA	5,651,986	7/29/97	Brem et al.	424	484	
	AB	5,871,437	2/16/99	Alt	600	3	
	AC	5,846,565	12/8/98	Brem et al.	424	486	
BS	AD	6,080,777	6/27/00	Schiff	514	449	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
BS	AE	WO 93/14787	8/5/93	WIPO		
	AF	WO 95/03036	2/2/95	WIPO		
	AG	WO 96/25176	8/22/96	WIPO		
	AH	WO 98/43618	10/8/98	WIPO		
BS	AI	DE 19754870 A1	8/6/98	Germany		X

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BS	AJ	Adelstein et al., "Does Paclitaxel Improve the Chemoradiotherapy of Locoregionally Advanced Esophageal Cancer? A Nonrandomized Comparison With Fluorouracil-Based Therapy," <i>Journal of Clinical Oncology</i> 18(10): 2032-2039, May 2000.
	AK	Amorino et al., "Enhancement of Radiation Effects by Combined Docetaxel and Carboplatin Treatment In Vitro," <i>Radiation Oncology Investigations</i> 7: 343-352, 1999.
	AL	Bartussek et al., "Accumulation of Mutant p53 <sup>V143A</sup> Modulates the Growth, Clonogenicity, and Radiochemosensitivity of Malignant Glioma Cells Independent of Endogenous p53 Status," <i>Experimental Cell Research</i> 253: 432-439, 1999.
	AM	Becker et al., "Phase I-II study of simultaneous radiotherapy and paclitaxel (taxol) in a twice a week (TIW) schedule for recurrent squamous cell carcinomas of the head and neck (SCCHN)," <i>European Journal of Cancer</i> 33: S193, Abstract No. 872, September 17, 1997.
BS	AN	Bladou et al., "Modèles in vitro et in vivo développés à partir de cancers prostatiques humains," <i>Prog. Urol.</i> 7(3): 384-396, June 1997.


EXAMINER

Brian Szmal

DATE CONSIDERED

12-5-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
110129.420C2APPLICATION NO.  
09/865,195

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT  
William L. Hunter et al.FILING DATE  
May 24, 2001GROUP ART UNIT  
3736RECEIVED  
APR 10 2002  
TECHNOLOGY

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
-----------------	------	---------	-----------------------

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BA	Britten et al., "Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens," <i>Radiotherapy and Oncology</i> 48: 329-334, 1998.
BB	Choy, H., "Combining Taxanes with Radiation for Solid Tumors," <i>Int. J. Cancer (Radiat. Oncol. Invest.)</i> 90: 113-127, 2000.
BC	Cordes et al., "Interaction of Paclitaxel (Taxol®) and Irradiation," <i>Strahlenther und Onkol.</i> 175(4): 175-181, April 1999.
BD	Dunst et al., "Preliminary Results of Simultaneous Radiochemotherapy with Paclitaxel for Urinary Bladder Cancer," <i>Strahlenther und Onkol.</i> 175(Suppl. 3): 7-10, 1999.
BE	Elomaa et al., "Squamous Cell Carcinoma is Highly Sensitive to Taxol, a Possible New Radiation Sensitizer," <i>Acta Otolaryngol (Stockh)</i> 115: 340-344, 1995.
BF	Ettinger, D.S., "Concurrent Paclitaxel-Containing Regimens and Thoracic Radiation Therapy for Limited-Disease Small Cell Lung Cancer," <i>Seminars in Radiation Oncology</i> 9(2, Suppl. 1): 148-150, April 1999.
BG	Farb et al., "Paclitaxel Polymer-Coated Stents Reduce Neointima," <i>70<sup>th</sup> Scientific Sessions of the American Heart Association</i> 96(8, Supplement I): I-608, Abstract No. 3394, 1997.
BH	Formenti et al., "Concurrent paclitaxel and radiation in locally advanced breast cancer," <i>European Journal of Cancer</i> 34: S12, Abstract No. 39, September 30, 1998.
BI	Glantz et al., "Weekly Paclitaxel With and Without Concurrent Radiation Therapy: Toxicity, Pharmacokinetics, and Response," <i>Seminars in Oncology</i> 23(6, Suppl. 16): 128-135, December 1996.
BJ	Haehnel et al., "Differential Effect of a Local Paclitaxel Release from a Biodegradable Stent Coating on Vascular Smooth Muscle Cells and Endothelial Cells in a Coculture Model," <i>48<sup>th</sup> Annual Scientific Session of the American College of Cardiology</i> 33(2, Suppl. A): 222A, Abstract No. 1011-24, February 1999.

EXAMINER

Brian Sena

DATE CONSIDERED

12-5-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
110129.420C2APPLICATION NO.  
09/865,195**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANT  
William L. Hunter et al.FILING DATE  
May 24, 2001GROUP ART UNIT  
3736**RECEIVED**  
APR 10 2002  
TECHNOLOGY CENTER**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
-----------------	------	---------	-----------------------

**OTHER PRIOR ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Hähnel et al., "Local Growth Inhibitory Effect of Paclitaxel Released by a Biodegradable Stent Coating on Vascular Smooth Muscle Cells," <i>47<sup>th</sup> Annual Scientific Session of the American College of Cardiology</i> 31(2, Suppl. A): 278A, Abstract No. 1114-102, February 1998.
	CB	Hähnel et al., "Local growth inhibitory effect of paclitaxel released by a biodegradable stent coating on vascular smooth muscle cells," <i>19<sup>th</sup> Congress of the European Society of Cardiology together with the 32<sup>nd</sup> Annual General Meeting of the Association of European Pediatric Cardiologists</i> 18: 460, Abstract No. 2696, 1997.
	CC	Hei et al., "Taxol and Ionizing Radiation: Interaction and Mechanisms," <i>Int. J. Radiation Oncology Biol. Phys.</i> 29(2): 267-271, 1994.
	CD	Hei and Hall, "Taxol, Radiation, and Oncogenic Transformation," <i>Cancer Res.</i> 53(6): 1368-1372, March 15, 1993.
	CE	Ingram and Redpath, "Subadditive Interaction of Radiation and Taxol <i>In Vitro</i> ," <i>Int. J. Radiation Oncology Biol. Phys.</i> 37(5): 1139-1144, 1997.
	CF	King et al., "Role of p53 and p16 Gene Alterations in Determining Response to Concurrent Paclitaxel and Radiation in Solid Tumors," <i>Seminars in Radiation Oncology</i> 9(2 Suppl. 1): 4-11, April 1999.
	CG	Kornowski et al., "Slow-Release Taxol Coated GRII <sup>TM</sup> Stents Reduce Neointims Formation in a Procine Coronary In-Stent Restenosis Model," <i>70<sup>th</sup> Scientific Sessions of the American Heart Association</i> 96(8): I-341, Abstract No. 1900, 1997.
	CH	Lee et al., "A Pilot Clinical Laboratory Trial of Paclitaxel and Endobronchial Brachytherapy in Patients With Non-Small Cell Lung Cancer," <i>Seminars in Radiation Oncology</i> 9(2 Suppl. 1): 121-129, April 1999.
	CI	Leonard et al., "Paclitaxel Enhances <i>in Vitro</i> Radiosensitivity of Squamous Carcinoma Cell Lines of the Head and Neck," <i>Cancer Research</i> 56: 5198-5204, November 15, 1996.
	CJ	Leung et al., "Polymeric Micellar Paclitaxel Phosphorylates Bcl-2 and Induces Apoptotic Regression of Androgen-Independent LNCaP Prostate Tumors," <i>The Prostate</i> 44: 156-163, 2000.

EXAMINER

DATE CONSIDERED

12-5-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
110129.420C2APPLICATION NO.  
09/865,195**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANT  
William L. Hunter et al.FILING DATE  
May 24, 2001GROUP ART UNIT  
3736REC  
APR 10 2002  
TECHNOLOGY CENTER**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
-----------------	------	---------	-----------------------

**OTHER PRIOR ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

38	DA	Li et al., "Potentiation of Ovarian OCA-1 Tumor Radioresponse by Poly (L-Glutamic Acid)-Paclitaxel Conjugate," <i>Int. J. Radiation Oncology Biol. Phys.</i> 48(4): 1119-1126, 2000.
	DB	Liebmann et al., "In Vitro Studies of Taxol as a Radiation Sensitizer in Human Tumor Cells," <i>Journal of the National Cancer Institute</i> 86(6): 441-446, March 16, 1994.
	DC	Lokeshwar et al., "Enhancement of Radiation Response of Prostatic Carcinoma by Taxol: Therapeutic Potential for Late-Stage Malignancy," <i>Anticancer Research</i> 15: 93-98, 1995.
	DD	Manifold et al., "Taxol Coated Stents in Oesophageal Adenocarcinoma," <i>Digestive Disease Week and the 99<sup>th</sup> Annual Meeting of the American Gastroenterological Association</i> 114(4) Part 2: A27, Abstract No. G0110, April 1998.
	DE	Mariotta et al., "Dexamethasone-Induced Enhancement of Resistance to Ionizing Radiation and Chemotherapeutic Agents in Human Tumor Cells," <i>Strahlenther und Onkol.</i> 175: 392-396, 1999.
	DF	Milas et al., "Combination of Taxanes With Radiation: Preclinical Studies," <i>Seminars in Radiation Oncology</i> 9(2, Suppl. 1): 12-26, April 1999.
	DG	Milas et al., "Enhancement of Tumor Radioresponse of a Murine by Paclitaxel," <i>Cancer Research</i> 54: 3506-3510, July 1, 1994.
	DH	Milross et al., "Enhanced Radioresponse of Paclitaxel-Sensitive and -Resistant Tumours <i>In Vivo</i> ," <i>European Journal of Cancer</i> 33(8): 1299-1308, July 1997.
	DI	Miyake et al., "Inhibition of Progression to Androgen-Independence by Combined Adjuvant Treatment with Antisense BCL-XL and Antisense Bcl-2 Oligonucleotides Plus Taxol After Castration in the Shionogi Tumor Model," <i>Int. J. Cancer</i> 86: 855-862, 2000.
	DJ	Mote et al., "Paclitaxel sensitizes multidrug resistant cells to radiation," <i>Anti-Cancer Drugs</i> 7: 182-188, 1996.
	DK	Niero et al., "Paclitaxel and Radiotherapy: Sequence-dependent Efficacy - A Preclinical Model," <i>Clinical Cancer Research</i> 5: 2213-2222, August 1999.
78	DL	Nisar Syed et al., "Brachytherapy for Primary and Recurrent Nasopharyngeal Carcinoma: 20 Years' Experience at Long Beach Memorial," <i>Int. J. Radiation Oncology Biol. Phys.</i> 47(5): 1311-1321, 2000.

EXAMINER

Brian Szma

DATE CONSIDERED

12-5-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



FORM PTO-1449  
(REV.7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
110129.420C2APPLICATION NO.  
09/865,195**SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

APPLICANT  
William L. Hunter et al.FILING DATE  
May 24, 2001GROUP/ART UNIT  
3730**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
-----------------	------	---------	-----------------------


**OTHER PRIOR ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

EA	Panvichian et al., "Signaling Network of Paclitaxel-Induced Apoptosis in the LNCaP Prostate Cancer Cell Line," <i>Urology</i> 54(4): 746-752, 1999.
EB	Petru et al., "Radiosensitivity Patterns of Four Human Ovarian Cancer Cell Lines <i>in Vitro</i> ," <i>Gynecologic Oncology</i> 64: 490-492, 1997.
EC	Plasswilm et al., "Schedule-Dependent Interaction of Paclitaxel (Taxol®) and Irradiation <i>In Vitro</i> ," <i>Radiation Oncology Investigations</i> 6: 10-17, 1998.
ED	Pradier et al., "Étude <i>in vitro</i> de l'association paclitaxel – radiothérapie sur une lignée cellulaire tumorale épidermoïde humaine," <i>Cancer/Radiother.</i> 3: 51-56, 1999.
EE	Preisler et al., "Combination of paclitaxel and radiation: genotoxicity <i>in vitro</i> in four mammalian cell lines," <i>Cancer Letters</i> 145: 29-33, 1999.
EF	Rosenthal et al., "Intensive Radiation Therapy Concurrent With Up to 7-Week Continuous-Infusion Paclitaxel for Locally Advanced Solid Tumors: Phase I Studies," <i>Seminars in Oncology</i> 24(1, Suppl. 2): S2-81 – S2-84, February 1997.
EG	Saito et al., "Cytotoxic effect of paclitaxel (taxol) either alone or in combination with irradiation in two rat yolk sac tumour cell lines with different radiosensitivities <i>in vitro</i> ," <i>Int. J. Radiat. Biol.</i> 73(2): 225-231, February 1998.
EH	Sedlák et al., "Taxol-enhanced cytotoxic effect of radiation in human promyelocytic leukemia cells: Relative resistance of multidrug-resistant HL-60 cells <i>in vitro</i> ," <i>Neoplasma</i> 44(3): 172-177, 1997.
EI	Snoek et al., "Differential Transactivation by the Androgen Receptor in Prostate Cancer Cells," <i>The Prostate</i> 36: 256-263, 1998.
EJ	Sorochinskii et al., "Antimitotic compounds as modifiers of the radiation lesion of cultured cells," <i>Tsitologiya i Genetika</i> 28(1): 3-9, January-February 1994.

EXAMINER *Brian Szwed* DATE CONSIDERED

12-5-02

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)

SUPPLEMENTAL

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
110129.420C2APPLICATION NO.  
09/865,195APPLICANT  
William L. Hunter et al.FILING DATE  
May 24, 2001GROUP ART UNIT  
3734

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
-----------------	------	---------	-----------------------

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	FA	Steinberg et al., "A Phase I Trial of Radiotherapy and Simultaneous 24-Hour Paclitaxel in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma," <i>Seminars in Oncology</i> 24(6, Suppl. 19): S19-51 – S19-56, December 1997.
	FB	Steren et al., "Taxol as a Radiation Sensitizer: A Flow Cytometric Study," <i>Gynecologic Oncology</i> 50: 89-93, 1993.
	FC	Vogt et al., "Simultaneous Paclitaxel and Radiotherapy: Initial Clinical Experience in Lung Cancer and Other Malignancies," <i>Seminars in Oncology</i> 24(4, Suppl. 12): S12-101 – S12-105, August 1997.
	FD	Voisard et al., "Paclitaxel-coated biodegradable stents inhibit proliferative activity and severely damage cytoskeletal components of smooth muscle cells from human coronary plaque material in vitro," <i>20<sup>th</sup> Congress of the European Society of Cardiology</i> 19: 376, Abstract No. P2109, August 1998.
	FE	Wehbe et al., "Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas," <i>J. Neurooncol.</i> 39(3): 245-251, September 1998.
	FF	Wenz et al., "Radiochemotherapy with Paclitaxel: Synchronization Effects and the Role of p53," <i>Strahlenther und Onkol.</i> 175(Suppl. III): 2-6, 1999.
	FG	Yalowich, J.C., "Effects of Microtubule Inhibitors on Etoposide Accumulation and DNA Damage in Human K562 Cells <i>in Vitro</i> ," <i>Cancer Research</i> 47: 1010-1015, February 15, 1987.
	FH	Yang et al., "In Vitro Efficacy of a Novel Chemoradiopotentiator – Taxoltere Metro," <i>Int. J. Radiation Oncology Biol. Phys.</i> 46(1): 159-163, 2000.
	FI	Yildiz et al., "Paclitaxel exposure time determines the nature of the interaction with radiation in HeLa cells: the role of apoptosis," <i>European Journal of Cancer</i> 36: 1426-1432, 2000.
	FJ	Zanelli et al., "Paclitaxel as a Radiosensitiser: A Proposed Schedule of Administration Based on <i>In Vitro</i> Data and Pharmacokinetic Calculations," <i>European Journal of Cancer</i> 33(3): 486-492, 1997.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).